One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Lianluo Smart Limited logo
Lianluo Smart Limited LLIT

Lianluo Smart Limited Financial Ratios 2020-2011 | LLIT

Brief overview of Lianluo Smart Limited's valuation and returns

This overview follows the five latest available observations from 2016 through 2020.

Market valuation is represented by P/E 107.05x (median 21.78x), EV/EBITDA 260.95x (median 13.93x), P/S 408.74x (median 326.62x). The combined multiple level is about 246.6% above the company's historical norm, leaving less valuation cushion.

Earnings yield calculated as 1/P/E is about 0.9%, showing current profit per unit of share price.

The latest available business-quality ratios are ROE -115.3%, ROA -53.6%, ROCE -89.3%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.

PEG is 1.66x. Price is well ahead of embedded growth, making market expectations demanding.

The cash conversion cycle decreased 14 days to 94.1 days, supporting working-capital efficiency.

Conclusion

Lianluo Smart Limited combines weak profitability with valuation above its historical norm, leaving limited cushion.

Annual Financial Ratios Lianluo Smart Limited

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-45.2 -74.3 -19.3 -56.1 -14.1 -8.2 -5.0 107.0 21.8 18.0

P/S

408.7 861.9 307.4 326.6 10.5 113.6 44.1 28.9 3.3 2.6

EV/EBITDA

-50.1 -109.7 -20.3 -75.8 -14.1 -13.6 -102.3 260.9 13.9 13.3

PEG

1.66 1.47 -0.27 0.82 0.31 0.13 0.0 -2.81 14.3 -0.49

P/B

52.1 -256.4 55.2 25.8 9.8 13.0 7.6 6.0 2.1 1.9

P/CF

-62.7 -197.8 -39.0 -52.9 -40.1 -35.4 -96.1 -1019.5 -67.9 -16.9

ROE %

-115.26 345.36 -285.89 -46.05 -69.82 -158.77 -152.07 5.58 9.84 10.76

ROA %

-53.60 -190.71 -156.35 -33.00 -58.80 -73.68 -114.41 4.74 8.39 8.86

ROCE %

-89.32 422.88 -218.11 -39.26 -65.92 -92.43 -8.36 1.56 12.75 11.90

DSO

214.8 334.4 479.1 173.6 4.7 57.0 238.5 678.2 219.5 262.6

DIO

50.0 532.5 649.7 488.8 2.9 1326.1 836.6 390.4 128.1 147.3

DPO

10.5 111.0 112.9 10.6 1.5 7.0 - 7.2 1.1 0.8

All numbers in USD currency

Multiples are an important financial analysis tool for the company Lianluo Smart Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Butterfly Network Butterfly Network
BFLY
$ 6.5 -2.1 % $ 1.61 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.45 -1.97 % $ 616 M israelIsrael
Beyond Air Beyond Air
XAIR
$ 2.52 10.34 % $ 20.9 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 6.99 -5.35 % $ 1.05 B usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 388.54 0.06 % $ 10.6 B usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.53 0.73 % $ 3.73 M usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.95 0.34 % $ 121 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 67.19 -1.94 % $ 1.99 B costa-ricaCosta-rica
Delcath Systems Delcath Systems
DCTH
$ 20.08 -0.96 % $ 719 M usaUSA
Electromed Electromed
ELMD
$ 27.2 1.29 % $ 225 M usaUSA
Inogen Inogen
INGN
$ 6.02 -1.64 % $ 160 M usaUSA
Globus Medical Globus Medical
GMED
$ 75.35 -1.34 % $ 10.2 B usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 86.87 -0.08 % $ 1.11 B usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 8.79 -4.2 % $ 249 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 3.17 -17.02 % $ 389 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
AxoGen AxoGen
AXGN
$ 50.89 0.49 % $ 2.34 B usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.7 -0.41 % $ 11.9 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 5.81 -0.34 % $ 362 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 14.54 1.18 % $ 1.11 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 62.25 -5.4 % $ 9.45 B usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 91.39 -1.32 % $ 4.99 B britainBritain
LENSAR LENSAR
LNSR
$ 4.97 -8.97 % $ 59.4 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 7.12 -9.94 % $ 282 M curacaoCuracao
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 2.81 0.18 % $ 114 M usaUSA
InspireMD InspireMD
NSPR
$ 0.78 9.49 % $ 50.2 M israelIsrael
InMode Ltd. InMode Ltd.
INMD
$ 13.26 -1.89 % $ 857 M israelIsrael